Trial Profile
A Phase I/II Study of Intratumoral Injection of the Small Molecule TLR8 Agonist VTX-2337 in Combination With Local Radiation in Low-Grade B-cell Lymphomas.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Motolimod (Primary)
- Indications B-cell lymphoma
- Focus Therapeutic Use
- Sponsors VentiRx Pharmaceuticals
- 04 Apr 2012 Actual patient number is 2 according to ClinicalTrials.gov.
- 04 Apr 2012 Actual patient number is 2 according to ClinicalTrials.gov.
- 04 Apr 2012 Planned end date changed from 1 Dec 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.